Read by QxMD icon Read


Baozhen Zhang, Zhilong Chen, Jinyu Han, Mengxia Li, Nihar R Nayak, Xiujun Fan
No effective treatments currently exist for placenta-associated pregnancy complications, and developing strategies for the targeted delivery of drugs to the placenta while minimizing fetal and maternal side effects remains challenging. Targeted nanoparticle carriers provide new opportunities to treat placental disorders. We recently demonstrated that a synthetic placental chondroitin sulfate A binding peptide (plCSA-BP) could be used to guide nanoparticles to deliver drugs to the placenta. In this protocol, we describe in detail a system for assessing the efficiency of drug delivery to the placenta by plCSA-BP that employs three separate methods used in combination: in vivo imaging, high-frequency ultrasound (HFUS), and high-performance liquid chromatography (HPLC)...
September 10, 2018: Journal of Visualized Experiments: JoVE
Mohamed S Sedky, Asmaa Hamouda, Hala Taha, Iman Zaky, Omayma Hassanain, Ahmed El Hemaly, Alaa ElHaddad
High-risk multisystem organ (RO+) Langerhans cell histiocytosis (LCH) has the least survival. We present the outcome of RO+ LCH in a pediatric single center. Fifty RO+ LCH patients, treated between 07/2007 and 07/2015, were retrospectively analyzed. Induction vinblastine (VBL) and prednisone (PRED) with intermediate-dose methotrexate (idMTX) was adopted until 2012 (n=20) wherein idMTX was omitted (n=30). The 3-year overall survival (OS) of MTX and non-MTX groups was 75% and 63%, respectively, P=0.537, while the event-free survival (EFS) was 36...
September 21, 2018: Journal of Pediatric Hematology/oncology
Kunihiko Umekita, Yayoi Hashiba, Yumi Kariya, Kazuyoshi Kubo, Shunichi Miyauchi, Ayako Aizawa, Kazumi Umeki, Hajime Nomura, Takeshi Kawaguchi, Motohiro Matsuda, Ichiro Takajo, Toshihiko Hidaka, Akihiko Okayama
OBJECTIVE: This study aimed to investigate the time-sequential changes of risk factors for adult T-cell leukemia (ATL) development in human T-cell leukemia virus type 1 (HTLV-1)-positive rheumatoid arthritis (RA) patients. METHODS: HTLV-1 infection was screened using particle agglutination assay and confirmed via western blotting in 365 RA patients. Twenty-three HTLV-1-positive RA patients were included in the study cohort. Blood samples were obtained from these patients at each observation time point...
September 24, 2018: Modern Rheumatology
Shivani B Kaushik, Mark G Lebwohl
Psoriasis is a chronic inflammatory disease which affects nearly 3% of the adult US population. Due to the chronic nature of the disease and need for long-term treatment, psoriasis is associated with substantial disease burden and negative impact on patients' quality of life. In the past, systemic agents such as methotrexate, cyclosporine, and acitretin have been the mainstay treatment for moderate to severe psoriasis. Multiple new molecular targets have been recently identified, and novel biologic therapies directed at these targets have been approved leading to a paradigm shift in psoriasis management...
September 23, 2018: International Journal of Dermatology
Christian J Apfelbacher, Robert F Ofenloch, Elke Weisshaar, Sonja Molin, Andrea Bauer, Vera Mahler, Andreas Heinrich, Ralph von Kiedrowski, Jochen Schmitt, Peter Elsner, Thomas L Diepgen
BACKGROUND: The CARPE registry was set up in 2009 to prospectively investigate the management of patients with chronic hand eczema (CHE). OBJECTIVES: To report comprehensive follow-up data from the CARPE registry. PATIENTS AND METHODS: We investigated sociodemographic and clinical characteristics, provision of medical care, physician-assessed outcomes, and patient-reported outcomes (PROs). Data were collected between 2009 and 2016, with up to 5 years of follow-up, and are reported descriptively...
September 24, 2018: Contact Dermatitis
Bin Luo, Yong-Yao Gu, Xiao-Dong Wang, Gang Chen, Zhi-Gang Peng
Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs were analyzed using the Database for Annotation, Visualization, and Integrated Discovery...
September 16, 2018: Pathology, Research and Practice
Dmitry Fridman, Eleanor Hawkins, Peer Dar, Scott Chudnoff, Ohad Rotenberg, Woojin Chong, Xianhong Xie, Sukrant Mehta, Mark Levie
OBJECTIVE: To report clinical experience with methotrexate (MTX) treatment for suspected but not definite ectopic pregnancy (EP). METHODS: This was a retrospective cohort study. All patients treated with MTX for presumed EP between 2000 and 2016 were included. Demographic, clinical, sonographic, and outcome data were collected and analyzed. RESULTS: A total of 820 patients were treated with MTX, 692 (84.4%) of which were lacking definitive features of EP; 155 (22...
September 23, 2018: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
Flora Hoodin, Leah LaLonde, Josh Errickson, Kristen Votruba, Rachel Kentor, Erin Gatza, Pavan Reddy, Sung Won Choi
Myeloablative conditioning allogeneic hematopoietic cell transplantation (HCT) puts patients at greater risk for significant cognitive and quality of life decline compared with recipients of reduced intensity conditioning or autologous HCT. Vorinostat, an HDAC inhibitor, has been shown to have neuroprotective and neurorestorative effects in preclinical models of neurological diseases. Thus, within the context of a myeloablative conditioning phase II clinical trial of vorinostat combined with tacrolimus and methotrexate for GVHD prophylaxis, we conducted an ancillary study to evaluate feasibility of assessing associations between Vorinostat and neurocognitive function and quality of life (ClinicalTrials...
September 19, 2018: Biology of Blood and Marrow Transplantation
Kurt T Barnhart, Mary D Sammel, Mary Stephenson, Jared Robins, Karl R Hansen, Wahid A Youssef, Nanette Santoro, Esther Eisenberg, Heping Zhang
OBJECTIVE: Pregnancy of unknown location (PUL) is not a diagnosis but a transient state used to classify a woman when she has a positive pregnancy test without definitive evidence of an intra-uterine or extra-uterine pregnancy on transvaginal ultrasonography. Management of a persisting PUL varies substantially, including expectant or active management. Active management can include uterine cavity evacuation or systemic administration of methotrexate. To date, no consensus has been reached on whether either management strategy is superior or non-inferior to the other...
September 19, 2018: Contemporary Clinical Trials
Thierry Vial, Anne Marie Patat, David Boels, Delphine Castellan, Antoine Villa, Hélène Theophile, Romain Torrents, Behrouz Kassai
OBJECTIVE: The objectives of this study are to carefully describe the context of methotrexate medication errors, to details medical consequences and management approaches, and to determine the rate of fatal outcome. METHODS: Data on methotrexate medication errors were obtained from the French network of Poison Control and Pharmacovigilance Centres which collected and documented reported drug-induced adverse effects. Cases were included if the intake was more than 2-fold the intended weekly dose or a weekly cumulative dose ≥ 30 mg and a follow-up of at least 4 days after the last dose...
September 19, 2018: Joint, Bone, Spine: Revue du Rhumatisme
Uri P Dior, Ricardo Palma-Dias, Karen L Reidy, Claudia Cheng, Martin Healey
STUDY OBJECTIVE: To describe the incidence, management, complications and define risk factors for conversion from medical to surgical treatment of Cesarean Scar Pregnancies (CSP). DESIGN: A retrospective clinical study (Canadian Task Force classification II-3). SETTING: A tertiary medical center. PATIENTS: All patients who were admitted and treated for CSP between 2008 and 2016. INTERVENTIONS: The cohort was divided according to management; demographic, clinical and sonographic data were collected...
September 19, 2018: Journal of Minimally Invasive Gynecology
Wanying Wang, Hua Zhou, Liang Liu
Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs (DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability. MTX benefits a large number of RA patients but partially suffered from side effects. A variety of side effects can be associated with MTX when treating RA patients, from mild to severe or discontinuation of the treatment. In this report, we reviewed the possible side effects that MTX might cause from the most common gastrointestinal toxicity effects to less frequent malignant diseases...
September 13, 2018: European Journal of Medicinal Chemistry
Déborah Gavanier, Hélène Leport, Jérome Massardier, Fatima Abbas, Anne-Marie Schott, Touria Hajri, François Golfier, Pierre-Adrien Bolze
OBJECTIVE: To evaluate the survival and functional outcome of patients with brain metastasis due to gestational trophoblastic neoplasia (GTN). METHODS: A 17-year retrospective study based on case review of women with brain metastasis from GTN identified by the electronic databases held in the French Reference Centre. PRIMARY OUTCOME MEASURE: 5-year overall survival calculated with the Kaplan-Meier method. SECONDARY OUTCOME MEASURES: causes of death, prognostic factors and functional outcomes...
September 21, 2018: International Journal of Clinical Oncology
Jaime Calvo Alén, Trinidad Pérez, Susana Romero Yuste, Iván Ferraz-Amaro, Juan José Alegre Sancho, José Antonio Pinto Tasende, Francisco Maceiras Pan, Juan Carlos Quevedo, M Vanesa Hernández-Hernández, Cristina Hidalgo Calleja, Alejandro San Martín Álvarez, María Isabel Tevar Sánchez, Raimon Sanmartí
OBJECTIVE: 1) To systematically and critically review the evidence of combined therapy with synthetic disease-modifying antirheumatic drugs (DMARD) in rheumatoid arthritis (RA); 2) To design practical recommendations on their use. METHODS: A systematic literature review (SLR) was performed with a sensitive bibliographic search strategy in Medline, EMBASE and Cochrane Library. We selected randomized clinical trials that analyzed the efficacy and/or safety of 1) combined therapy of synthetic compared with sequential therapy of synthetic DMARD in early RA; and 2) combination of methotrexate+leflunomide or triple therapy with synthetic DMARD in established RA refractory to synthetic DMARD...
September 18, 2018: Reumatología Clinica
Eliana Rezende Adami, Claudia Rita Corso, Natalia Mulinari Turin-Oliveira, Claudia Martins Galindo, Letícia Milani, Maria Caroline Stipp, Georgia Erdmann do Nascimento, Andressa Chequin, Luisa Mota da Silva, Sérgio Faloni de Andrade, Rosangela Locatelli Dittrich, José Ederaldo Queiroz-Telles, Giseli Klassen, Edneia A S Ramos, Lucimara M C Cordeiro, Alexandra Acco
The present study investigated the antineoplastic effects of pectic polysaccharides that were extracted from green sweet pepper (Capsicum annuum [CAP]) in the Ehrlich carcinoma in mice and in human mammary tumor lineages. After the subcutaneous inoculation of 2 × 106 Ehrlich tumor cells, Female Swiss mice received 50, 100, or 150 mg/kg CAP or vehicle orally once daily or methotrexate (2.5 mg/kg, i.p., every 5 days) for 21 days. CAP dose-dependently reduced Ehrlich tumor growth. It also reduced the viability of MCF-7, MDA-MB-231, and MDA-MB-436 human mammary cell lineages...
December 1, 2018: Carbohydrate Polymers
Jyoti Bajpai, Arun Chandrasekharan, Vijai Simha, Vikas Talreja, Ashay Karpe, Nikihil Pandey, Ashish Singh, Bharat Rekhi, Tushar Vora, Jaya Ghosh, Shripad Banavali, Sudeep Gupta
PURPOSE: Metastatic osteosarcoma is largely treated with high-dose methotrexate (HDMTX)-based therapy, especially in the pediatric population. This mandates complex pharmacokinetic monitoring in a costly inpatient setting to mitigate unpredictable serious toxicities. Hence, a non-HDMTX-based regimen is worth exploring, especially in India and low- and middle-income countries. MATERIALS AND METHODS: All consecutive treatment-naïve patients with metastatic osteosarcoma were prospectively treated on the novel OGS-12 protocol consisting of sequential doublets of doxorubicin, cisplatin, and ifosfamide...
September 2018: Journal of Global Oncology
Sameer Rastogi, Aditi Aggarwal, Akash Tiwari, Vinod Sharma
PURPOSE: Osteosarcoma (OS) is a relatively chemosensitive primary bone tumor, with the peak age of onset occurring in late childhood and early adolescence. The treatment paradigm of nonmetastatic OS has typically been multimodality therapy, including neoadjuvant and adjuvant chemotherapy with definitive surgery. Over the years, various permutations and combinations of chemotherapeutic agents have been used. However, the majority of recent trials have still used high-dose methotrexate as the backbone, with cisplatin and doxorubicin (MAP)...
September 2018: Journal of Global Oncology
Clémentine Puech, Sophie Hodin, Valérie Forest, Zhiguo He, Patrick Mismetti, Xavier Delavenne, Nathalie Perek
Endothelial cells are main components of the Blood-Brain Barrier (BBB) and form a tight monolayer that regulates the passage of molecules, with the ATP-Binding Cassette (ABC) transporters efflux pumps. We have developed a human in vitro model of HBEC-5i endothelial cells cultivated alone or with human astrocytes conditioned medium on insert. HBEC-5i cells showed a tight monolayer within 14 days, expressing ZO-1 and claudin 5, a low apparent permeability to small molecules, with a TEER stability during five days...
September 18, 2018: International Journal of Pharmaceutics
Hunter John Piegols, Marilia Takada, Maciej Parys, Thomas Dexheimer, Vilma Yuzbasiyan-Gurkan
Feline oral squamous cell carcinomas (FOSCC) are highly aggressive neoplasms with short survival times despite multimodal treatment. FOSCC are similar to squamous cell carcinomas of the head and neck (SCCHN) in humans, which also present therapeutic challenges. The current study was undertaken to identify novel chemotherapeutics using FOSCC cell lines. A high throughput drug screen using 1,952 drugs was performed to identify chemotherapeutics for further investigation. Two of the drugs identified in the drug screen, actinomycin D and methotrexate, and two drugs with similar molecular targets to drugs found to be efficacious in the screening, dinaciclib and flavopiridol, were selected for further investigation...
September 4, 2018: Oncotarget
Eugeniusz J Kucharz, Marcin Stajszczyk, Anna Kotulska-Kucharz, Bogdan Batko, Marek Brzosko, Sławomir Jeka, Piotr Leszczyński, Maria Majdan, Marzena Olesińska, Włodzimierz Samborski, Piotr Wiland
Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular nucleus and inhibits the inflammation process via a new pathway (inhibition of the Janus kinases), which is unavailable to biological medicines. Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA...
2018: Reumatologia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"